Executive Snapshot

Due to widespread product demand, FY2025 delivery remained robust, with total revenue of $58.7 billion (+8%) and core EPS of $9.16 (+11%).

The short-term story is "guidance + mix": FY2026 guidance anticipates low double-digit Core EPS growth and mid-to-high single-digit revenue growth.

Revenue of $15.5 billion, compared to $15.78 billion, and Core EPS of $2.12, compared to $2.18, were both very close to estimates, albeit slightly below consensus.

Oncology remains the largest source of earnings, accounting for 44% of FY2025 product revenue and $25.6 billion (+14%) from the oncology franchise.

Market context: AZN's recent returns were +4.27% (1M) and +2.28% (1W), and it moved between $122 and $196 over a 52-week period.

What’s moving the stock now

Two factors that can push emotion in opposing ways are at the heart of the current situation:

The management's outlook for FY2026 indicates that growth will continue, which is significant since it shows that they are confident in the product portfolio and pipeline cadence's ability to continue compounding earnings.

The narrative that investors tell themselves on a daily basis is being shaped by drug-level stories. Examples include news about oncology pipeline updates (where "next approvals" frequently affect multiples even before revenue appears) and lupus treatment Saphnelo, where regulatory decisions can swiftly change perception.

Expectations Gap

Q4 headline comparison (Actual vs Consensus):

• Revenue: $15.5B vs $15.78B (about 1.8% below consensus)
• Core EPS: $2.12 vs $2.18 (about 2.8% below consensus)

Framing guidance (what is more important than the Q4 delta):

The company's FY2026 estimate is for low double-digit Core EPS growth and mid-to-high single-digit sales growth, indicating that it anticipates earnings power to continue growing rather than plateauing after a single quarter's noise.

Operating read-through

Oncology is the anchor, and Mix is performing the heavy lifting.

AstraZeneca's product revenue for FY2025 is variable, but not "equal-weighted." With 44% of product revenue, oncology is the largest contributor and continues to set the standard. In FY2025, the oncology division generated $25.6 billion (+14%), a growth rate that can sustain the larger model even amid instability in smaller brands.

Strong demand signal from Saphnelo, but headlines may cause ambiguity

The main factors driving Saphnelo's $203M Q4 revenues (+37% YoY) were continued launches and U.S. demand. That demand signal is clear.

However, because regulatory decisions, label extensions, and competition updates can swiftly alter the addressable market narrative, the market tends to view immunology treatments as "headline-sensitive." This implies that, in practice, Saphnelo can boost growth while also causing mood swings, even when quarterly sales appear strong.

Reinvestment and margin: the model continues to finance expansion

AstraZeneca's 82% gross margin for FY2025 allows it to make profitable investments in R&D and new product launches. The company is attempting to keep expansion "self-funded" by scaling core earnings and sustaining pipeline investment, rather than picking one over the other. This is the main analytical point.

Positioning plus valuation

Price behavior

The 52-week range for AZN, from $122 to $196, indicates that the market has already significantly repriced the company across several narrative regimes (growth confidence vs. headline risk). Constructive recent performance (+4.27% over one month) usually indicates that investors are shifting toward the "guidance durability" viewpoint.

Multiples context

A significant compression is evident in the valuation series, which ranges from 64.77x (2022) to about 30x (TTM/current at 30.44x). Simply said, AZN is no longer priced like a peak-multiple momentum stock, but the market is still rewarding quality and pipeline.

This means that short-term gains often depend more on better-than-expected execution (launch traction, clean regulatory outcomes, and confidence that FY2026 guidance is realistic) than on "good results."

Catalysts

Follow-through on FY2026 messaging: any supplementary information that strengthens (or erodes) trust in the FY2026 growth algorithm.

Improved visibility through pipeline and oncology updates: early indications of launch momentum (including Datroway, currently valued at $40M).

The sentiment gap can be rapidly narrowed or widened by any clarity regarding the regulatory/label story for Saphnelo.

Risks

The fact that Q4 earnings were slightly below the consensus (Revenue ~1.8%, Core EPS ~2.8%) shows how sensitive earnings are to expectations and how even "solid" quarters can fall short if expectations are high.

Immunology headline-driven volatility: short-term price action may still be dominated by regulatory or label results even if Q4 Saphnelo sales were $203M, up 37% year over year.

Multiple risk: the stock may be sensitive to any indication that the FY2026 forecast is becoming more difficult to meet, given that its valuation is still at 30 times (TTM/current).

Conclusion

The most recent results from AstraZeneca support a well-known yet investable structure: a scale pharmaceutical brand with cancer driving growth, with a FY2026 outlook aimed at maintaining trust. The stock's next move is likely to be more influenced by follow-through on FY2026 execution (launch traction, clean regulatory outcomes, and ongoing mix strength) than by a single quarter's print, since the quarter itself was close to forecasts but slightly weaker than consensus.

Shariah compliance snapshot

AstraZeneca is Shariah-compliant under AAOIFI methodology as its healthcare business is permissible, impure income is only 0.51% (below the 5% threshold), and financial ratios, interest-bearing assets 12.77% and interest-bearing liabilities 13.92%, are within acceptable limits.

Sources

• IR Results Presentation - (AstraZeneca)
• AstraZeneca PLC - (Gurufocus)
• AstraZeneca rises as cancer drugs power Q4 beat - (SeekingAlpha)
• AstraZeneca PLC. Stock Analysis - (Musaffa)

Disclaimer: Musaffa Academy articles are provided for informational purposes only, and are not research reports or legal, tax, investment, or financial advice. Content may include historical or hypothetical data; past performance does not guarantee future results.

Stock screenings, halal status, grades, and classifications are based on AAOIFI methodology and the oversight of Musaffa’s Shariah scholars. The content is not tailored to your financial situation, risk tolerance, or investment objectives. Always conduct your own research or consult a qualified financial advisor before making decisions.

Musaffa Islamic Social Responsible Investing (MISRI) proprietary rankings are internally developed by Musaffa and are currently in beta. While we continuously work to improve accuracy and reliability, no guarantees are made regarding completeness or correctness.

Logos and brand names are used for identification only and do not imply endorsement. Information is accurate as of the publication date and may change. All content, materials, and methodologies are the exclusive property of Musaffa and are protected by copyright law.

For full details, please visit: https://musaffa.com/disclaimer